Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3828706 | Revista Clínica Española | 2006 | 5 Pages |
Abstract
Intravenous immunoglobulin therapy (IVIg) has been used in the treatment of autoimmune bullous diseases unresponsive to conventional therapy in recent years. The action mechanism, which is not well known, suggests a wide spectrum of immunoregulation. In the last five years, several studies on patients with unresponsive pemphigus vulgaris with a clinical and serological outcome after IVIg administration in 80%-90% of cases have been published. We report the case of 3 patients with pemphigus vulgaris in whom we measured autoantibody titers to desmoglein 3 and 1 during 8 months. In spite of the clinical improvement, no significant decrease in antibody concentration was observed. Therapy with IVIg, although it has clinical benefit, did not decrease antibody values in our patients and thus it mayneed to be combined with immuno suppressant that inhibit pathogen antibody production.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
R. Suárez-Fernándeza, I. Longoa, J.A. Avilésa, C. Buenoa, M. RodrÃguez-Mahoub, P. Lázaroa,